MADRID, Spain, April 27, 2017 /PRNewswire/ --
Under the title of "R&D Day", PharmaMar(MCE: PHM) hosted an investor meeting in New York to demonstrate its evolution and potential in the areas of R&D. Various members of PharmaMar's management team, together with key global opinion leaders in oncology
With the aim of defining and contextualizing PharmaMar's research work, the meeting saw the participation of Dr Melinda Telli, an oncologist from the School of Medicine of the University of Stanford, and Dr Martin Forster, an oncologist from the University College of London. Both experts explained their investigative experience and the progress and positive results that have been obtained up to now with lurbinectedin (PM1183), the most advanced molecule in the PharmaMar pipeline, a transcription inhibitor which is directed at treating various cancer including hereditary breast cancer (discussed by Dr Telli) and small cell lung cancer (discussed by Dr Forster) respectively.
In addition, Sue Friedman represented the patients' association Facing Our Risks of Cancer Empowered (FORCE), of which she is the Executive Director, with the aim of highlighting the importance of joint investigation and innovation in oncology by oncological centres, opinion leaders and patients.
Representing the company's management team, José María Fernández, President of PharmaMar, presented the company's five-year growth plan following on from the basis of the progress that has been delivered to date. "Today, PharmaMar has a treatment option that is accessible for oncological patients, but our project is to keep growing". In addition, Luis Mora, Managing Director of PharmaMar's Oncology Business Unit, added that the company's aims are directed at "being able to deliver three valid products for a minimum of five indications to the medical community in the near future, following the successful example of Yondelis®".
The presentation by Arturo Soto, director of Clinical Development of PharmaMar´s Oncology Business Unit, included the earlier clinical data for Lurbinectedin in ovarian, small cell lung, breast and endometrial cancers, which preceded the current CORAIL and ATLANTIS Phase III studies with lurbinectedin which assess the efficacy in platinum-resistant ovarian cancer and in small-cell lung cancer, respectively. Information was also offered about several clinical trials in progress as well as a general vision of the company's strategy.
Jose Luis Moreno, Director of Capital Markets also presented the company financials, balance sheet and income statement as of year-end 2016 and updated certain expectations for 2017.
Finally, Pascal Besman, PharmaMar's Chief Operations Officer in the United States , told the attendees about the company's development plan in the country. This involves establishing a solid communication structure with key groups within the health system, patient and care giver associations, oncologists and the media.
The meeting was recorded and the content will be available for viewing in the Events Calendar section of the website https://www.pharmamar.com.
Contact: Media Relations (+ 34 638 79 62 15) and Investor Relations (+34 914444500)
Subscribe to our Free Newsletters!
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...View All